Sulindac sulfone (BioDeep_00000054170)

   

human metabolite Endogenous blood metabolite Chemicals and Drugs


代谢物信息卡片


2-{5-fluoro-1-[(4-methanesulfonylphenyl)methylidene]-2-methyl-1H-inden-3-yl}acetic acid

化学式: C20H17FO4S (372.0831534)
中文名称:
谱图信息: 最多检出来源 Bos taurus(endogenous) 23.53%

分子结构信息

SMILES: CC1=C(CC(O)=O)C2=C(C=CC(F)=C2)C1=CC1=CC=C(C=C1)S(C)(=O)=O
InChI: InChI=1S/C20H17FO4S/c1-12-17(9-13-3-6-15(7-4-13)26(2,24)25)16-8-5-14(21)10-19(16)18(12)11-20(22)23/h3-10H,11H2,1-2H3,(H,22,23)

描述信息

Sulindac sulfone is a metabolite of sulindac. Sulindac is a non-steroidal anti-inflammatory drug of the arylalkanoic acid class that is marketed in the UK & U.S. by Merck as Clinoril. (Wikipedia)

同义名列表

4 个代谢物同义名

2-{5-fluoro-1-[(4-methanesulfonylphenyl)methylidene]-2-methyl-1H-inden-3-yl}acetic acid; {6-fluoro-3-[(4-methanesulfonylphenyl)methylidene]-2-methylinden-1-yl}acetic acid; Sulindac sulphone; Sulindac sulfone



数据库引用编号

2 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有:

  • PubMed: 来源于PubMed文献库中的文献信息,我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表,这个列表按照代谢物同时出现的文献数量降序排序,取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘,得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序,取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中,存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称,可以跳转到相关代谢物的信息页面。



文献列表

  • Shuhao Yu, Zhizhong Guo, Yan Guan, Yi-Yu Lu, Pei Hao, Yixue Li, Shi-Bing Su. Combining ZHENG Theory and High-Throughput Expression Data to Predict New Effects of Chinese Herbal Formulae. Evidence-based complementary and alternative medicine : eCAM. 2012; 2012(?):986427. doi: 10.1155/2012/986427. [PMID: 22666299]
  • Bhagavathi A Narayanan, Bandaru S Reddy, Maarten C Bosland, Dominick Nargi, Lori Horton, Carla Randolph, Narayanan K Narayanan. Exisulind in combination with celecoxib modulates epidermal growth factor receptor, cyclooxygenase-2, and cyclin D1 against prostate carcinogenesis: in vivo evidence. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007 Oct; 13(19):5965-73. doi: 10.1158/1078-0432.ccr-07-0744. [PMID: 17908994]
  • Bing Zhu, Lakshmi Vemavarapu, W Joseph Thompson, Samuel J Strada. Suppression of cyclic GMP-specific phosphodiesterase 5 promotes apoptosis and inhibits growth in HT29 cells. Journal of cellular biochemistry. 2005 Feb; 94(2):336-50. doi: 10.1002/jcb.20286. [PMID: 15526282]
  • Samir E Witta, Daniel L Gustafson, A Scott Pierson, Alexander Menter, Scott N Holden, Michele Basche, Martha Persky, Cindy L O'Bryant, Chan Zeng, Anna Baron, Michael E Long, Amy Gibbs, Karen Kelly, Paul A Bunn, Daniel C Chan, Patrick Pallansch, S Gail Eckhardt. A phase I and pharmacokinetic study of exisulind and docetaxel in patients with advanced solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004 Nov; 10(21):7229-37. doi: 10.1158/1078-0432.ccr-03-0181. [PMID: 15534096]
  • Daniel L Gustafson, Michael E Long, Joseph A Zirrolli, Mark W Duncan, Scott N Holden, A Scott Pierson, S Gail Eckhardt. Analysis of docetaxel pharmacokinetics in humans with the inclusion of later sampling time-points afforded by the use of a sensitive tandem LCMS assay. Cancer chemotherapy and pharmacology. 2003 Aug; 52(2):159-66. doi: 10.1007/s00280-003-0622-z. [PMID: 12759775]